Compass Pathways Q3 2026 Earnings: Launch Spending Widens Operating Loss

Compass Pathways (Nasdaq: CMPS) reported no revenue in either Q3 2026 or the year-earlier quarter and a diluted net loss of $0.31 per share, compared with $1.44 per share in Q3 2025. The net loss narrowed to $9.8 million from $137.7 million, but operating loss widened as spending shifted from clinical development toward preparations for a potential COMP360 launch. Cash stood at $444.0 million at September 30, 2026.

Core Financial Results

The sharp reduction in net loss did not reflect an improvement in underlying operations. Operating expenses rose approximately 39% to $56.4 million, while a $40.8 million non-cash gain from revaluing warrant liabilities significantly reduced the reported net loss.

R&D expenses declined following completion of the COMP360 Phase 3 program in treatment-resistant depression, while SG&A increased as Compass invested in commercial infrastructure, market access, reimbursement capabilities, supply-chain readiness and other launch activities.

These are GAAP results. Compass did not provide adjusted earnings, adjusted EBITDA or other non-GAAP measures.

Launch Costs Rose Even as Warrant Accounting Reduced the Net Loss

Compass reduced quarterly R&D spending by $3.9 million, mainly because clinical trial costs declined after completion of the COMP360 Phase 3 program in treatment-resistant depression. Lower discovery spending following earlier program terminations also contributed, partly offset by higher consulting and contractor costs.

That reduction was more than outweighed by a $19.8 million increase in SG&A. As a result, operating loss widened by $15.9 million even though the reported net loss improved by $127.9 million.

The difference came primarily from warrant accounting. Compass recorded a $40.8 million warrant revaluation gain in Q3 2026, compared with a $101.3 million loss a year earlier. Because the warrant liability changes with the company’s share price, management cautioned that it can cause substantial variability in reported net income or loss. The operating loss therefore provides a clearer view of the quarter’s underlying expense trend.

COMP360 Moves Toward Its NDA and a Potential 2027 Launch

As of the November 3, 2026 earnings release, Compass expected to complete the rolling New Drug Application for COMP360 in treatment-resistant depression within two weeks. Rolling review was already underway. The company said its National Priority Voucher could shorten FDA review to one or two months, although approval and an accelerated timeline remain uncertain.

Compass continued to target a first-half 2027 launch, subject to FDA approval and the required rescheduling process. Commercial preparations include building a sales team, training providers, establishing patient-support programs and developing reimbursement and market-access capabilities. Management believes COMP360 could use an existing network of more than 8,500 centers equipped to provide multi-hour treatments.

The regulatory package includes two positive Phase 3 trials. Compass said 52-week open-label COMP005 data showed additional benefit from another 25 mg dose during Part C, extending durability to one year, while COMP006 provided six-month data. The company described COMP360 as generally well tolerated and said its clinical program included more than 1,000 participants.

Compass is also continuing a late-stage, potentially registration-enabling PTSD study. Separately, it is working with the U.S. Department of Veterans Affairs on a randomized study of COMP360 in veterans with treatment-resistant depression, including participants with concurrent PTSD.

Balance Sheet and Cash Position

Cash and cash equivalents increased to $444.0 million at September 30, 2026, from $149.6 million at December 31, 2025. Debt rose to $51.0 million from $31.6 million over the same period.

The supplied results did not include operating cash flow or free cash flow figures. Consequently, the increase in cash should not be interpreted as quarterly cash generation, and the company’s operating cash burn cannot be calculated from this release alone.

Financial Guidance

Compass expects its current cash position to fund operating expenses and capital expenditures into 2028. This runway extends beyond its targeted first-half 2027 launch window, but the company did not provide more detailed expense or capital-spending guidance.

Risks Investors Need to Monitor

• FDA review remains uncertain: The NDA was nearing completion, but COMP360 had not yet received approval. The National Priority Voucher may not result in the proposed one-to-two-month review timeline.
• Rescheduling could affect launch timing: Because COMP360 contains a Schedule I controlled substance, the DEA and relevant states must complete rescheduling before U.S. commercialization can begin.
• Commercial costs are rising before revenue: Launch preparations drove a sharp increase in SG&A and widened the operating loss. Delays in approval, reimbursement or adoption could extend this period of elevated spending without product revenue.
• Warrant accounting can distort reported earnings: Changes in the warrant liability may continue to produce large non-cash gains or losses, making net loss volatile from quarter to quarter.
• The disclosed cash runway is finite: Management expects funding into 2028, but did not quantify requirements beyond that period or provide quarterly cash-flow data in the release.

Summary

Compass Pathways is shifting from late-stage COMP360 development toward regulatory review and potential commercialization. Lower R&D spending was outweighed by substantially higher launch-related SG&A, widening the operating loss even as a non-cash warrant gain reduced the reported net loss. The $444.0 million cash balance supports the planned launch window, while FDA approval, rescheduling, reimbursement and commercial execution are the principal milestones to watch.